Clinical trials: T-Cell Non-Hodgkin Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
The purpose of this research is to find the best dose of genetically modified T-cells, to study the safety of this treatment, and to see how well it works in treating patients with B cell non-Hodgkin lymphoma that has come back…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma
- Trial name
- NCT03277729
- Testing
- Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma, Extranodal NK-T-Cell
Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma
The purpose of this study is to evaluate whether a semi-quantitative interpretation using the liver SUVmax as reference can better interpret 18F- FDG PET/CT and predict disease progression during chemotherapy or survival in…
- Trial name
- NCT03051542
- Testing
- 18F-FDG PET/CT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
This is a single-center, nonrandomized, open-label dose-escalation study followed by dose-expansion of CD19- CD34t metabolically programmed CAR T-cell therapy in adult patients with relapsed or refractory CD19 B-cell non-Hodgkin…
- Trial name
- NCT05702853
- Testing
- Cyclophosphamide injection, Fludarabine Injection, CD19-CD34t metabolically programmed CAR transduced T-cells
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Medical University of South Carolina
NK/T-cell Lymphoma, Peripheral T-cell Lymphoma (PTCL)
Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma
This study will test whether anti-EBV autologous TCR-T cell injection is safe and effective for patients with relapsed or refractory EBV-positive lymphoma who have HLA-A11:01.
- Conditions
- NK/T-cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), DLBCL
- Trial name
- Anti-EBV TCR-T (NCT07162012)
- Testing
- EBV TCR-T
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Leukemia, B-Cell, Lymphoma, B-Cell
Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies
This single arm, open-label, multi-center clinical trial is studying CD19 targeted chimeric antigen receptor T cells therapy in treating patients with CD19 positive malignant B-cell derived leukemia and lymphoma that is relapsed…
- Trial name
- NCT02813837
- Testing
- CD19CART
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Innovative Cellular Therapeutics Co., Ltd.
Extranodal NK/T-cell Lymphoma, Nasal Type
GPED Regimen for Relapsed/Refractory or Advanced ENKTCL
The purpose of this study is to evaluate the efficacy and safety of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients (ENKTCL).
- Trial name
- NCT04405375
- Testing
- gemcitabin, Pegaspargase, Etoposide
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Beijing Tongren Hospital
Lymphoma, Chronic Lymphocytic Leukemia
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
The goal of this study is to characterize the safety, maximum tolerated dose (MTD) and preliminary efficacy profile of IPI-145 given in combination with rituximab, or bendamustine plus rituximab, to subjects with select…
- Conditions
- Lymphoma, Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, T-cell Lymphoma
- Trial name
- NCT01871675
- Testing
- IPI-145, Rituximab, Bendamustine
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- SCRI Development Innovations, LLC
Lymphoma, Non-Hodgkin Lymphoma, B-Cell
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory lymphoma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells.
- Trial name
- NCT05312801
- Testing
- BAFF CAR-T
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Luminary Therapeutics
Natural Killer T-cell Lymphoma
Predictive Value of a SNP Signature and Liquid Biopsy in Natural Killer T-cell Lymphoma
The purpose of this study is to determine the Predictive value of a SNP signature and liquid biopsy in patients with natural killer T-cell lymphoma.
- Trial name
- NCT04423536
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Sun Yat-sen University
Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma of Soft Tissue
A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies
A Study of Murine CD19 CAR-T Cells Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies.
- Trial name
- NCT04532281
- Testing
- Murine CD19 CAR-T cells
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhejiang University
Mycosis Fungoides
Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)
This is an open label, single arm, single-center, pilot study of concurrent phototherapy and POTELIGEO (mogamulizumab-kpkc) in early-stage mycosis fungoides.
- Trial name
- PLIGHT (NCT06235281)
- Testing
- Mogamulizumab-Kpkc, Phototherapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Peripheral T-cell Lymphoma
Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma
The purpose of this study is to determine the efficacy and the safety profile and toxicity of a combination of Velcade™ (bortezomib) with a standard chemotherapy regimen (ACVBP [doxorubicin, cyclophosphamide, vindesine…
- Trial name
- NCT00136565
- Testing
- Velcade, Doxorubicin, Prednisone
- Where
- 5 sites in Belgium, France
- Volunteers
- 60 people
- Sponsor
- Lymphoma Study Association
Peripheral T Cell Lymphoma
Transplantation After Complete Response In Patients With T-cell Lymphoma
Peripheral T-cell lymphoma (PTCL) encompasses a broad range of post-thymic (i.e., mature) sub-entities as defined by the 2017 WHO classification.
- Trial name
- TRANSCRIPT (NCT05444712)
- Testing
- Chemotherapy + follow up, Chemotherapy + ASCT + follow up
- Where
- 48 sites in France
- Volunteers
- 204 people
- Sponsor
- Hospices Civils de Lyon
Non-small Cell Lung Cancer, Gastric Carcinoma
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are.
- Conditions
- Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma
- Trial name
- NCT04254107
- Testing
- SEA-TGT, sasanlimab, brentuximab vedotin
- Where
- 36 sites in United States, Canada and 4 more
- Volunteers
- 133 people
- Sponsor
- Seagen Inc.
Lymphoma, B-Cell
A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma
This is a prospective, single-arm, single-center, open-label, single-dose dose finding and expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor efficacy profile of LCAR-L10D in subjects with…
- Trial name
- NCT03593109
- Testing
- Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Newly Diagnosed Peripheral T-cell Lymphoma
A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
The goal of this clinical trial is to compare Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL. The main question it aims to answer are: •Whether Chi-BEAM improves patient survival compared to BEAM group…
- Trial name
- NCT05931263
- Testing
- C-BEAM Regimen, BEAM Regimen
- Where
- China
- Volunteers
- 104 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Anxiety Disorder, Chronic Myeloproliferative Disorders
Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation
RATIONALE: Music therapy may be effective in relieving pain and emotional distress in patients who are undergoing cancer therapy.
- Conditions
- Anxiety Disorder, Chronic Myeloproliferative Disorders, Depression, Lymphoma
- Trial name
- NCT00014482
- Testing
- pain therapy, psychosocial assessment and care
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
This phase II trial is studying how well giving bendamustine hydrochloride, etoposide, dexamethasone, and filgrastim together for peripheral stem cell mobilization works in treating patients with refractory or recurrent lymphoma…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01110135
- Testing
- bendamustine hydrochloride, dexamethasone, filgrastim
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Washington
Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
This phase II trial studies how well reduced intensity donor stem cell transplant works in treating patients with hematologic malignancies.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT01384513
- Testing
- Fludarabine, Busulfan, Total Body Irradiation (TBI)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Leukemia, Lymphoma
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00006042
- Testing
- filgrastim, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.